212 related articles for article (PubMed ID: 27180762)
1. Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia.
Lopez-Lopez E; Gutierrez-Camino A; Astigarraga I; Navajas A; Echebarria-Barona A; Garcia-Miguel P; Garcia de Andoin N; Lobo C; Guerra-Merino I; Martin-Guerrero I; Garcia-Orad A
Pharmacogenomics; 2016 May; 17(7):731-41. PubMed ID: 27180762
[TBL] [Abstract][Full Text] [Related]
2. Mir-pharmacogenetics of Vincristine and peripheral neurotoxicity in childhood B-cell acute lymphoblastic leukemia.
Gutierrez-Camino Á; Umerez M; Martin-Guerrero I; García de Andoin N; Santos B; Sastre A; Echebarria-Barona A; Astigarraga I; Navajas A; Garcia-Orad A
Pharmacogenomics J; 2018 Dec; 18(6):704-712. PubMed ID: 29282364
[TBL] [Abstract][Full Text] [Related]
3. Variants in vincristine pharmacodynamic genes involved in neurotoxicity at induction phase in the therapy of pediatric acute lymphoblastic leukemia.
Martin-Guerrero I; Gutierrez-Camino A; Echebarria-Barona A; Astigarraga I; Garcia de Andoin N; Navajas A; Garcia-Orad A
Pharmacogenomics J; 2019 Dec; 19(6):564-569. PubMed ID: 30723315
[TBL] [Abstract][Full Text] [Related]
4. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia.
Egbelakin A; Ferguson MJ; MacGill EA; Lehmann AS; Topletz AR; Quinney SK; Li L; McCammack KC; Hall SD; Renbarger JL
Pediatr Blood Cancer; 2011 Mar; 56(3):361-7. PubMed ID: 21225912
[TBL] [Abstract][Full Text] [Related]
5. Severe life threatening neurotoxicity in a child with acute lymphoblastic leukemia receiving posaconazole and vincristine.
Jain S; Kapoor G
Pediatr Blood Cancer; 2010 May; 54(5):783. PubMed ID: 20205256
[No Abstract] [Full Text] [Related]
6. Lack of association of the CEP72 rs924607 TT genotype with vincristine-related peripheral neuropathy during the early phase of pediatric acute lymphoblastic leukemia treatment in a Spanish population.
Gutierrez-Camino A; Martin-Guerrero I; Lopez-Lopez E; Echebarria-Barona A; Zabalza I; Ruiz I; Guerra-Merino I; Garcia-Orad A
Pharmacogenet Genomics; 2016 Feb; 26(2):100-2. PubMed ID: 26618658
[TBL] [Abstract][Full Text] [Related]
7. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia.
Diouf B; Crews KR; Lew G; Pei D; Cheng C; Bao J; Zheng JJ; Yang W; Fan Y; Wheeler HE; Wing C; Delaney SM; Komatsu M; Paugh SW; McCorkle JR; Lu X; Winick NJ; Carroll WL; Loh ML; Hunger SP; Devidas M; Pui CH; Dolan ME; Relling MV; Evans WE
JAMA; 2015 Feb; 313(8):815-23. PubMed ID: 25710658
[TBL] [Abstract][Full Text] [Related]
8. Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited-sampling, population modelling approach.
Moore AS; Norris R; Price G; Nguyen T; Ni M; George R; van Breda K; Duley J; Charles B; Pinkerton R
J Paediatr Child Health; 2011 Dec; 47(12):875-82. PubMed ID: 21658147
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphisms in candidate genes are not associated with increased vincristine-related peripheral neuropathy in Arab children treated for acute childhood leukemia: a single institution study.
Zgheib NK; Ghanem KM; Tamim H; Aridi C; Shahine R; Tarek N; Saab R; Abboud MR; El-Solh H; Muwakkit SA
Pharmacogenet Genomics; 2018 Aug; 28(8):189-195. PubMed ID: 30119132
[TBL] [Abstract][Full Text] [Related]
10. Severe Vincristine-related Neurotoxicity in 5 Patients With Pediatric Acute Lymphoblastic Leukemia Requiring Discontinuation of Vincristine: A Description of Long-term Outcome.
Egan-Sherry D; Bhuta R; Cole PD; Gennarini LM; Kahn JM; Sulis ML; DeNardo BD; Welch JJG
J Pediatr Hematol Oncol; 2021 Oct; 43(7):e997-e999. PubMed ID: 34001785
[TBL] [Abstract][Full Text] [Related]
11. Association of CYP3A5 Expression and Vincristine Neurotoxicity in Pediatric Malignancies in Turkish Population.
Kayilioğlu H; Kocak U; Kan Karaer D; Percin EF; Sal E; Tekkesin F; Isik M; Oner N; Belen FB; Yilmaz Keskin E; Okur A; Albayrak M; Kaya Z; Pinarli FG; Yenicesu I; Karadeniz C; Oguz A; Gursel T
J Pediatr Hematol Oncol; 2017 Aug; 39(6):458-462. PubMed ID: 28697165
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomics of Vincristine-Induced Peripheral Neuropathy Implicates Pharmacokinetic and Inherited Neuropathy Genes.
Wright GEB; Amstutz U; Drögemöller BI; Shih J; Rassekh SR; Hayden MR; Carleton BC; Ross CJD;
Clin Pharmacol Ther; 2019 Feb; 105(2):402-410. PubMed ID: 29999516
[TBL] [Abstract][Full Text] [Related]
13. Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia.
Plasschaert SL; Groninger E; Boezen M; Kema I; de Vries EG; Uges D; Veerman AJ; Kamps WA; Vellenga E; de Graaf SS; de Bont ES
Clin Pharmacol Ther; 2004 Sep; 76(3):220-9. PubMed ID: 15371983
[TBL] [Abstract][Full Text] [Related]
14. Involvement of miRNA polymorphism in mucositis development in childhood acute lymphoblastic leukemia treatment.
Gutierrez-Camino Á; Umerez M; Lopez-Lopez E; Santos-Zorrozua B; Martin-Guerrero I; de Andoin NG; Ana S; Navajas A; Astigarraga I; Garcia-Orad A
Pharmacogenomics; 2018 Dec; 19(18):1403-1412. PubMed ID: 30479191
[TBL] [Abstract][Full Text] [Related]
15. Incidence of vincristine induced neurotoxicity in children with acute lymphoblastic leukemia and its correlation with nutritional deficiencies.
Dudeja S; Gupta S; Sharma S; Jain A; Sharma S; Jain P; Aneja S; Chandra J
Pediatr Hematol Oncol; 2019 Sep; 36(6):344-351. PubMed ID: 31514565
[TBL] [Abstract][Full Text] [Related]
16. Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients.
Renbarger JL; McCammack KC; Rouse CE; Hall SD
Pediatr Blood Cancer; 2008 Apr; 50(4):769-71. PubMed ID: 18085684
[TBL] [Abstract][Full Text] [Related]
17. A case of severe toxicity during coadministration of vincristine and piperacillin: are drug transporters involved in vincristine hypersensitivity and drug-drug interactions?
Le Guellec C; Benz-de Bretagne I; Jonville-Bera AP; Tarfaoui N; Andres CR; Gendrot C; Jourdain A
J Pediatr Hematol Oncol; 2012 Nov; 34(8):e341-3. PubMed ID: 22627576
[TBL] [Abstract][Full Text] [Related]
18. Vincristine-induced unilateral ptosis in a child.
Gursel O; Sari E; Altun D; Atay AA; Akin R
Pediatr Neurol; 2009 Dec; 41(6):461-3. PubMed ID: 19931172
[TBL] [Abstract][Full Text] [Related]
19. Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity.
Guilhaumou R; Solas C; Bourgarel-Rey V; Quaranta S; Rome A; Simon N; Lacarelle B; Andre N
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1633-8. PubMed ID: 21968951
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetic association with neurotoxicity in Hispanic children with acute lymphoblastic leukaemia.
McClain CA; Bernhardt MB; Berger A; Bernini JC; Marquez-Do D; Winslow R; Scheurer ME; Schafer ES
Br J Haematol; 2018 Jun; 181(5):684-687. PubMed ID: 28419449
[No Abstract] [Full Text] [Related]
[Next] [New Search]
